+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

The World Market for Cancer Diagnostics, 6th Edition (Histology [ISH, IHC, HPV, Pap], Flow Cytometry, PSA, CEA, Liquid Biopsy, FOB and Other Rapid, Image Cytometry, Sequencing, Digital Pathology, Molecular Assays)

  • ID: 3398431
  • Report
  • Region: Global
  • 861 Pages
  • Kalorama Information
1 of 2
Cancer testing is maturing from personalized medicine to precision medicine, where protein and molecular biomarkers are essential for precise diagnosis, therapy selection, therapy monitoring and early detection of cancer recurrence.  The World Market for Cancer Diagnostics, 6th Edition provides authoritative and complete analysis of the cancer testing industry, with expert market sizing and opportunity assessment.  
Segment markets for cancer testing are comprehensively covered in Kalorama Information's World Market for Cancer Diagnostics, 6th. Edition.  The report contains detailed market data on the following IVD segments for their use in cancer diagnostics:
  • IVD Market for Cancer Tests
  • Service Test Market
  • in situ hybridization (ISH)
  • Immunohistochemistry (IHC)
  • FOB and Other Rapid Tests
  • PSA, CEA and Other Markers
  • Flow Cytometry
  • Pap and HPV Testing
  • Molecular Oncology Assays
  • Tissue Microrrays
  • Methylated DNA
  • Circulating Tumor Cells
  • Next-Generation Sequencing Technologies
  • Tissue Function Tests
  • Companion Testing, CDX Products and Deals
The Race for Prevention Supports a Market for Innovative Diagnostic Tools 
Given the unfortunate statistics of cancer in the developed world, innovation is a must. Growth rates in cancer testing tends to be higher than in other IVD fields. Diagnostic tests for effective cancer screening are obviously needed more than ever. As this report goes to print a number of significant developments are taking place in cancer follow up. New imaging tools, bioinformatics, sequencing technologies, improved histological tests are among the trends discussed in this multifaceted report.  The importance of this industry is seen in the flurry of investments and financing arrangements made and the number of partnerships and purchases/mergers where one or both companies are involved in cancer diagnostics.  This report contains 
  • Investments and Financing Agreements For Cancer Diagnostics Companies
  • Selected Agreements Between Cancer Diagnostic Companies
  • Selected Agreements Between Cancer Diagnostic Companies and Other Diagnostic Companies 
  • Selected Agreements Between Cancer Diagnostic Companies and Pharmaceutical or Biopharmaceutical Companies
  • Selected Cancer Diagnostic Company Agreements with Academic or Other Non-Profit Organizations
  • Selected Acquisitions of Cancer Diagnostic Companies
Complete Market and Trend Analysis 
In five previous editions. Kalorama has defined the oncology testing market, based on primary research of the market with particular attention to important market trends.  These trends are more important to understand than today's numbers.  Market analysis in this report covers world markets for in vitro cancer diagnostics, however the reader will find a bias toward the developed areas of the globe -- N. America, Japan and Western Europe. However cancer is a growing global problem and where possible the report covers cancer testing in the more industrialized developing countries of Latin America and Asia Pacific. 
The phenomenon of test personalization comes under many guises as pharmacogenomic, pharmacogenetic, companion tests, and represents one of the fastest growing segments of the market for cancer tests. It has emerged fully from research into clinical practice. Instrumentation now automates many of the sample preparation and assay steps that were formerly labor intensive. New tests are being launched all the time. Some personalized cancer tests are CE Marked and FDA-cleared and many more are in development. More and more laboratories offer complex panels of tests that help physicians evaluate disease risk and make therapeutic decisions. Government and private healthcare payers have recognized the value of new molecular tools and are agreeing to pay for them. 
Unparalleled Review of Cancer Testing Competitors: Top Tier IVD Companies And Specialist Companies 
This report is written from the point of view of diagnostic modalities for the detection and management of cancer and in particular solid tumors. The technology to detect cancers of the blood - lymphomas, myelomas and leukemia - is mature and well established. The routine complete blood count screens for blood cell abnormalities and is followed by bone marrow analysis and flow cytometric studies of the blood cell surface markers. These to arrive at a more specific diagnosis. As such this report does not discuss area of hematological cancer diagnosis in great detail. 
The emphasis is on in vitro diagnostic tests, however a discussion of the role of diagnostics in cancer management, must include in vitro and in vivo tests. The two are inextricably linked. The same cell markers used in flow cytometry and antibodies used for immunoassays to detect elements of the immunity process are used as vectors for imaging agents to detect tumors and to monitor the extent of cancer metastasis. 
In addition to extensive reviews of products on the market and in development in each segment, the report provides detailed company profiles in several sections, including the following companies:
  • M Genomics Ltd.
  • 20/20 GeneSystems, Inc.
  • AB SCIEX
  • Abbott Laboratories
  •  Abcodia Ltd.
  • Abingdon Health Ltd
  • Abnova Corporation
  • ACT Genomics Co., Ltd.
  • Adaptive Biotechnologies Corporation
  • Admera Health (a GENEWIZ company)
  • Advanced Cell Diagnostics
  • Affymetrix, Inc.
  • Agena Bioscience Inc.
  • Agendia NV
  • Agilent Technologies Inc.
  • Alere Inc.
  • Ambry Genetics Corp.
  • Amoy Diagnostics Co., Ltd.
  • ANGLE plc
  • ApoCell, Inc.
  • Applied Proteomics, Inc.
  • Applied Spectral Imaging, Inc.
  • Arbor Vita Corporation
  • ARKRAY, Inc.
  • ARUP Laboratories
  • Astra Biotech GmbH
  • Asuragen, Inc.
  • AsymmetRx Medical, Inc.
  • Atossa Genetics Inc.
  •  AutoGenomics, Inc
  • Avant Diagnostics, Inc. (formerly Arrayit Diagnostics Inc.)
  • Axela, Inc
  • AXO Science
  • Beckman Coulter, Inc. (subsidiary of Danaher Corporation)
  • Becton, Dickinson and Company (BD)
  •  BGI-Shenzhen
  • The Binding Site Group Ltd.
  • Biocare Medical, LLC
  • Biocartis SA
  • Biocept, Inc.
  •  Biodesix, Inc.
  • BioFluidica
  • BioGenex
  • Biological Dynamics Inc.
  • BioMarker Strategies
  • bioMérieux SA
  • BioMosaics
  • Bio-Rad Laboratories, Inc.
  • Bio-Reference Laboratories, Inc. (BRLI)
  • BioSystems
  • bioTheranostics (a bioMérieux company)
  • Biotype Diagnostic GmbH
  • BioView Ltd
  • Boditech Med Inc.
  •  Cancer Genetics, Inc.
  •  Canopus Bioscience Ltd.
  • Caprion, Inc.
  • Caris Life Sciences
  • Castle Biosciences, Inc.
  • CDx Diagnostics
  • Celerus Diagnostics, Inc.
  • Cellmid Ltd.
  • Centogene AG
  • Cepheid
  •  Cernostics
  • Cirdan Imaging Ltd
  • Clarient Diagnostic Services, Inc. (a GE Healthcare company)
  • Clearbridge BioMedics Pte Ltd
  • Color Genomics, Inc.
  • Counsyl, Inc.
  • Cube Dx GmbH
  • Cynvenio Biosystems, Inc.
  • CytoTest Inc.
  • Dako A/S (an Agilent company)
  • Danaher Corporation
  • DermTech, Inc.
  • DiaCarta, Inc.
  • DiaSorin S.p.A.
  • DiaTech Oncology
  • EDP Biotech Corporation
  • Eiken Chemical Co., Ltd.
  •  EntroGen, Inc.
  • Enzo Biochem, Inc
  • Enzo Life Sciences, Inc.
  • Enzo Clinical Labs, Inc.
  • Epic Sciences, Inc.
  • Epigenomics AG
  • Eutropics Pharmaceuticals
  • Exact Sciences Corporation
  •  Exosome Diagnostics, Inc.
  • Fluxion Biosciences, Inc.
  • Foundation Medicine, Inc.
  • Fujirebio Inc.
  • Fujirebio Diagnositics, Inc.
  •  GE Healthcare
  • Genalyte, Inc.
  • GeneCentric Diagnostics, Inc.
  • Genection, Inc. (an Invivoscribe company)
  • GeneDx
  • GeneNews Limited
  • Genetic Technologies Limited / Phenogen Sciences, Inc. (U.S. division)
  • GenomeDx Biosciences
  • Genomica S.A.U.
  • Genomic Health, Inc.
  •  Genomic Vision
  • Genoptix (a Novartis company)
  • GenPath / GenPath Women’s Health and GenPath Oncology
  • Guardant Health, Inc.
  • HalioDx
  • Healgen Scientific LLC
  • Helomics Corporation
  • Hologic, Inc.
  • HTG Molecular Diagnostics, Inc.
  •  Human Longevity, Inc.
  • Icellate AB
  • Ikonisys, Inc.
  • Illumina, Inc.
  • ImCare BioTech
  • Immunovia AB
  • IncellDx, Inc.
  • Inform Genomics, Inc.
  • Financings
  • Other Agreements
  • Inivata Ltd.
  • Innovations Exchange Pte Ltd (INEX)
  • Insight Genetics, Inc.
  • IntegraGen SA
  • Integrated Diagnostics, Inc.
  • Invitae Corporation
  •  Invivoscribe Technologies, Inc.
  • Iris BioTechnologies Inc.
  • Janssen Diagnostics / Janssen Diagnostics BVBA
  • Janssen Diagnostics, LLC
  • Laboratory Corporation of America (LabCorp) / Integrated Genetics
  •  Leica Biosystems Inc. (a Danaher company)
  • Leica Microsystems (a Danaher company)
  • Lifecode, Inc.
  • MagArray, Inc.
  • Martell Diagnostic Laboratories, Inc.
  • Matrix-Bio, Inc.
  • Mayo Medical Laboratories and Mayo Clinic
  • Medical & Biological Laboratories Co., Ltd. (MBL)
  • MBL International Corporation
  •  MDxHealth SA
  • Metamark Genetics, Inc.
  • MetaStat, Inc.
  • MolecularMD Corporation
  • Multiplicom NV
  • Myriad Genetics, Inc.
  • Myriad RBM, Inc.
  • NanoIVD, Inc.
  • NanoString Technologies, Inc.
  • NeoGenomics, Inc. / NeoGenomics Laboratories
  •  NewGene Ltd.
  • New Oncology AG
  • Nuclea Biotechnologies, Inc.
  • Ohmx Corporation
  • Omnyx
  • Oncimmune Ltd.
  • Oncimmune (USA) LLC (acquired by HDL Inc.)
  • Health Diagnostic Laboratory, Inc.
  • OncoCyte Corporation
  • OncoDNA SA
  • OncoHealth Corp.
  • Oncolab, Inc.
  • Oncolys BioPharma Inc.
  • Oncompass GmbH
  • Onconome, Inc.
  • OncoPlex Diagnostics (OncoPlexDx)
  • Oncospire Genomics
  • OPKO Health, Inc. / OPKO Diagnostics
  •  Orion Genomics
  • Ortho-Clinical Diagnostics
  •  OvaGene Oncology Inc.
  • Oxford Cancer Biomarkers Ltd.
  • Oxford Gene Technology
  • Pacific Edge Limited
  • Pathway Genomics Corporation
  • Personal Genome Diagnostics, Inc.
  • PGXL Laboratories
  • Phenomenome Discoveries Inc.
  • Polymedco, Inc.
  • PreTect AS
  • PrognosDx Health, Inc.
  • Provista Diagnostics, Inc.
  • QIAGEN N.V.
  • QuanDx
  • Quanterix Corporation
  • QuantuMDx Group
  • Quest Diagnostics
  •  RainDance Technologies, Inc.
  • Randox Laboratories Ltd
  • Rarecells SAS
  • Response Genetics, Inc.
  •  Rheonix, Inc.
  • RiboMed Biotechnologies, Inc.
  • Roche
  •  Rosetta Genomics Ltd.
  •  ScheBo-Biotech AG
  • ScreenCell
  • Sequenom, Inc.
  •  Siemens Healthcare Diagnostics
  • Symbiodx
  • Sysmex Corporation
  • TeloVISION, LLC
  • Theranostics Health Inc.
  • Thermo Fisher Scientific, Inc.
  • Tosoh Corporation
  • Tosoh Bioscience, Inc.
  • Transgenomic, Inc.
  • TrimGen Corporation
  • TrovaGene, Inc.
  •  Vela Diagnostics
  • Ventana Medical Systems, Inc. (member of the Roche Group)
  • Veracyte, Inc.
  •  Wako Diagnostics
  • Wako Pure Chemical Industries, Ltd.,
Note: Product cover images may vary from those shown
2 of 2
ONE: EXECUTIVE SUMMARY
Overview Scope and Methodology Market Overview Prognosis for Growth
TWO: INTRODUCTION
Diagnosis and Treatment of Cancer Point of View THREE: TECHNOLOGIES USED IN CANCER DIAGNOSTICS
Chromosome Analysis (Karyotyping) Cytology/Histology Stains Tests for Fecal Occult Blood Immunoassays Overview - Immunoassays Immunoassay Instrument Platforms Immunohistochemistry (IHC) Flow Cytometry Fluorescence in situ Hybridization (FISH) and Chromogenic in situ Hybridization(CISH) Nucleic Acid Amplification Technologies Analysis of Gene Expression Patterns (Gene Signatures) Microarrays Protein Microarrays DNA Microarrays Chromosomal Microarrays Tissue Microarrays Sequencing Technologies Sanger Sequencing Early Next Generation Sequencing Technologies Sequencing by Synthesis (SBS) Supported Oligonucleotide Ligation and Detection (SOLiD) Ion Torrent Sequencing True Single Molecule Sequencing (tSMS) Single Molecule Real Time (SMRT) Sequencing DNA Nanoball Sequencing Nanopore Sequencing Other Sequencing Technologies Mass Spectrometry Mass Spectrometry Technology Research and Clinical Applications of Mass Spectrometry Circulating Tumor DNA (Cell Free DNA) Circulating Tumor Cells (CTCs) Cell-Based Assays (Live Cell Cancer Tests) Digital Pathology and Image Cytometry Information Technology
FOUR: CANCER DIAGNOSTICS – APPLICATIONS
Assess Risk of Developing Cancer Cancer Screening Cancer Screening – Pap Smear and Human Papillomavirus (HPV) Testing Colorectal Cancer Screening Prostate Cancer Screening Screening for Other Cancers Diagnosis/Prognosis/Monitoring of Cancer Personalized Medicine/Companion Diagnostics/Precision Testing Drug Metabolism Predicting Response to Therapy FIVE: CANCER DIAGNOSTIC MARKETS
In Vitro Diagnostic Kits Marketed to Clinical Laboratories Point-of-Care Tests for Cancer Clinical Laboratory Test Services
SIX: DEALS – CANCER DIAGNOSTICS
Investments and Financing Agreements for Cancer Diagnostic Companies Agreements with Other Companies Acquisitions of Cancer Diagnostic Companies Selected Other Agreements
SEVEN: CANCER DIAGNOSTICS – MARKET DRIVERS AND CHALLENGES
Cancer Diagnostic Market Drivers Advances in Technology Changing the Future of Cancer Diagnostics Impact of Companion Diagnostic Tests Limited Tissue from Biopsies for Growing Number of Cancer Tests Laboratory Developed Tests and the FDA Cost and Reimbursement Issues Physician Education, Acceptance, and Use of New Cancer Tests Competition Future Prospects
EIGHT: IN VITRO CANCER DIAGNOSTICS MARKET ANALYSIS
In Vitro Cancer Diagnostics Market by Geographical Distribution Clinical Laboratory Testing Market – Cancer Diagnostics In Vitro Cancer Diagnostics Market Segments Histology/Cytology Immunoassays Rapid Tests Molecular (Nucleic Acid-Based) Assays NINE: COMPANY PROFILES: CANCER DIAGNOSTIC COMPANIES
M Genomics Ltd. 20/20 GeneSystems, Inc. AB SCIEX Abbott Laboratories  Abcodia Ltd. Abingdon Health Ltd Abnova Corporation ACT Genomics Co., Ltd. Adaptive Biotechnologies Corporation Admera Health (a GENEWIZ company) Advanced Cell Diagnostics Affymetrix, Inc.  Agena Bioscience Inc. Agendia NV Agilent Technologies Inc.  Alere Inc.  Ambry Genetics Corp. Amoy Diagnostics Co., Ltd. ANGLE plc ApoCell, Inc. Applied Proteomics, Inc. Applied Spectral Imaging, Inc. Arbor Vita Corporation ARKRAY, Inc. ARUP Laboratories Astra Biotech GmbH Asuragen, Inc. AsymmetRx Medical, Inc. Atossa Genetics Inc.  AutoGenomics, Inc Avant Diagnostics, Inc. (formerly Arrayit Diagnostics Inc.) Axela, Inc AXO Science Beckman Coulter, Inc. (subsidiary of Danaher Corporation)  Becton, Dickinson and Company (BD)  BGI-Shenzhen The Binding Site Group Ltd. Biocare Medical, LLC Biocartis SA Biocept, Inc.  Biodesix, Inc. BioFluidica BioGenex Biological Dynamics Inc. BioMarker Strategies bioMérieux SA  BioMosaics Bio-Rad Laboratories, Inc.  Bio-Reference Laboratories, Inc. (BRLI)  BioSystems bioTheranostics (a bioMérieux company) Biotype Diagnostic GmbH BioView Ltd Boditech Med Inc.  Cancer Genetics, Inc.  Canopus Bioscience Ltd. Caprion, Inc. Caris Life Sciences Castle Biosciences, Inc. CDx Diagnostics Celerus Diagnostics, Inc. Cellmid Ltd. Centogene AG Cepheid  Cernostics Cirdan Imaging Ltd Clarient Diagnostic Services, Inc. (a GE Healthcare company) Clearbridge BioMedics Pte Ltd Color Genomics, Inc. Counsyl, Inc. Cube Dx GmbH Cynvenio Biosystems, Inc. CytoTest Inc. Dako A/S (an Agilent company) Danaher Corporation DermTech, Inc. DiaCarta, Inc. DiaSorin S.p.A. DiaTech Oncology EDP Biotech Corporation Eiken Chemical Co., Ltd.  EntroGen, Inc. Enzo Biochem, Inc Enzo Life Sciences, Inc. Enzo Clinical Labs, Inc. Epic Sciences, Inc. Epigenomics AG  Eutropics Pharmaceuticals Exact Sciences Corporation  Exosome Diagnostics, Inc. Fluxion Biosciences, Inc. Foundation Medicine, Inc.  Fujirebio Inc. Fujirebio Diagnositics, Inc.  GE Healthcare  Genalyte, Inc. GeneCentric Diagnostics, Inc. Genection, Inc. (an Invivoscribe company) GeneDx GeneNews Limited Genetic Technologies Limited / Phenogen Sciences, Inc. (U.S. division)  GenomeDx Biosciences Genomica S.A.U. Genomic Health, Inc.  Genomic Vision  Genoptix (a Novartis company) GenPath / GenPath Women’s Health and GenPath Oncology Guardant Health, Inc. HalioDx Healgen Scientific LLC Helomics Corporation Hologic, Inc.  HTG Molecular Diagnostics, Inc.  Human Longevity, Inc. Icellate AB Ikonisys, Inc. Illumina, Inc.  ImCare BioTech Immunovia AB IncellDx, Inc. Inform Genomics, Inc. Financings Other Agreements Inivata Ltd. Innovations Exchange Pte Ltd (INEX) Insight Genetics, Inc. IntegraGen SA  Integrated Diagnostics, Inc. Invitae Corporation  Invivoscribe Technologies, Inc. Iris BioTechnologies Inc. Janssen Diagnostics / Janssen Diagnostics BVBA Janssen Diagnostics, LLC Laboratory Corporation of America (LabCorp) / Integrated Genetics  Leica Biosystems Inc. (a Danaher company) Leica Microsystems (a Danaher company) Lifecode, Inc. MagArray, Inc. Martell Diagnostic Laboratories, Inc. Matrix-Bio, Inc. Mayo Medical Laboratories and Mayo Clinic Medical & Biological Laboratories Co., Ltd. (MBL) MBL International Corporation  MDxHealth SA  Metamark Genetics, Inc. MetaStat, Inc. MolecularMD Corporation Multiplicom NV Myriad Genetics, Inc. Myriad RBM, Inc.  NanoIVD, Inc. NanoString Technologies, Inc.  NeoGenomics, Inc. / NeoGenomics Laboratories  NewGene Ltd. New Oncology AG Nuclea Biotechnologies, Inc. Ohmx Corporation Omnyx Oncimmune Ltd. Oncimmune (USA) LLC (acquired by HDL Inc.) Health Diagnostic Laboratory, Inc. OncoCyte Corporation OncoDNA SA OncoHealth Corp. Oncolab, Inc. Oncolys BioPharma Inc. Oncompass GmbH Onconome, Inc. OncoPlex Diagnostics (OncoPlexDx) Oncospire Genomics OPKO Health, Inc. / OPKO Diagnostics  Orion Genomics Ortho-Clinical Diagnostics  OvaGene Oncology Inc. Oxford Cancer Biomarkers Ltd. Oxford Gene Technology Pacific Edge Limited  Pathway Genomics Corporation Personal Genome Diagnostics, Inc. PGXL Laboratories Phenomenome Discoveries Inc. Polymedco, Inc. PreTect AS PrognosDx Health, Inc. Provista Diagnostics, Inc. QIAGEN N.V. QuanDx Quanterix Corporation QuantuMDx Group Quest Diagnostics  RainDance Technologies, Inc. Randox Laboratories Ltd Rarecells SAS Response Genetics, Inc.  Rheonix, Inc. RiboMed Biotechnologies, Inc. Roche  Rosetta Genomics Ltd.  ScheBo-Biotech AG ScreenCell Sequenom, Inc.  Siemens Healthcare Diagnostics Symbiodx Sysmex Corporation  TeloVISION, LLC Theranostics Health Inc. Thermo Fisher Scientific, Inc.  Tosoh Corporation Tosoh Bioscience, Inc.  Transgenomic, Inc. TrimGen Corporation TrovaGene, Inc.  Vela Diagnostics Ventana Medical Systems, Inc. (member of the Roche Group) Veracyte, Inc.  Wako Diagnostics Wako Pure Chemical Industries, Ltd., , LIST OF EXHIBITS

ONE: EXECUTIVE SUMMARY
Table 1-1: Worldwide Cancer Diagnostic Market, 2014 and 2019 (Global Cancer IVD Market, Clinical Laboratory Services) (in millions USD)
TWO: INTRODUCTION
Table 2-1: Estimated Global Incidence and Mortality due to Cancer, 2012
THREE: TECHNOLOGIES USED IN CANCER DIAGNOSTICS
Table 3-1: Selected Examples of Companies Marketing Fecal Occult Blood Tests Table 3-2: Selected Companies with Immunoassays and/or Automated Immunoassay Platforms on the Market or In Development for Cancer Diagnostics Table 3-3: Selected Examples of Companies Marketing Rapid Lateral Flow Tests for Tumor Antigens Table 3-4: Selected Companies with Immunohistochemistry Tests on the Market or In Development for Cancer Diagnostics Table 3-5: Selected Companies Marketing Flow Cytometry Platforms or Consumables Table 3-6: Selected Companies with in situ hybridization tests on the Market or In Development for Cancer Diagnostics (Company, Comment, Market Status) Table 3-7: Selected Companies with PCR or Other Nucleic Acid Amplification Based Tests for Cancer Diagnostics Table 3-8: Selected Examples of Companies Analyzing Gene Expression Patterns (“Gene Signatures”) in Tissues Table 3-9: Selected Companies Developing/Marketing Cancer Diagnostic Products Based on Microarray Technologies Table 3-10: Selected Sequencing Technologies and Platforms Table 3-11: Selected Diagnostic Companies and Clinical Laboratories with Sequencing-Based Cancer Tests Table 3-12: Selected Companies Developing/Marketing Mass Spectrometry- Based Oncology Diagnostic Tests Table 3-13: Selected Examples of Companies Developing/Commercializing Cancer Diagnostic Assays Based on ctDNA Table 3-14: Selected Companies Working with Circulating Tumor Cells (CTCs) Table 3-15: Selected Companies Developing or Commercializing Cell-Based Assays for Cancer Diagnostics Table 3-16: Selected Digital Pathology Companies
FOUR: CANCER DIAGNOSTICS – APPLICATIONS
Table 4-1: Selected Companies Developing/Marketing Assays to Determine Risk of Cancer Table 4-2: Selected Companies Developing/Marketing Diagnostic Tests for HPV Table 4-3: Selected Companies Developing/Marketing Cancer IVD Tests for Colorectal Cancer Screening Table 4-4: Selected Companies Developing/Marketing Screening Tests for Prostate Specific Antigen Table 4-5: Selected Companies Developing/Marketing Other Tests for Prostate Cancer Table 4-6: Selected Companies Developing/Marketing Screening Tests for Other Cancers Table 4-7: Selected Widely Used Tumor Markers Table 4-8: Selected Companies Developing/Marketing Tests for Diagnosis/Prognosis/Monitoring of Cancer Table 4-9: Selected Companies Developing/Marketing Tests for Drug Metabolism – To Personalize Treatment of Cancer Table 4-10: Selected Companies Developing/Marketing Tests to Predict Response to Therapy; Precision Medicine Table 4-11: Selected FDA Cleared/Approved Companion Diagnostic Tests
FIVE: CANCER DIAGNOSTIC MARKETS
Table 5-1: Selected Examples - Companies Developing and Marketing Cancer Diagnostics Tests and Platforms to Clinical Laboratories Table 5-2: Selected Examples - Companies Developing and/or Marketing Pointof-Care and/or Rapid Platforms and Tests for Cancer – Moving Beyond Lateral Flow Table 5-3: Selected Examples - Companies Developing and/or Offering Cancer Diagnostic Tests as Laboratory Developed Tests
SIX: DEALS – CANCER DIAGNOSTICS
Table 6-1: Selected Investments and Other Financing Agreements for CancerDiagnostic Companies Table 6-2: Selected Agreements Between Cancer Diagnostic Companies and Other Diagnostic Companies or Clinical Laboratories Table 6-3: Selected Agreements Between Cancer Diagnostic Companies and Pharmaceutical or Biopharmaceutical Companies Table 6-4: Selected Agreements Between Two Cancer Diagnostic Companies Table 6-5: Selected Other Cancer Diagnostic Company Agreements Table 6-6: Selected Acquisitions of Cancer Diagnostic Companies Table 6-7: Selected Cancer Diagnostic Company Agreements with Academic or Other Non-Profit Organizations
EIGHT: IN VITRO CANCER DIAGNOSTICS MARKET ANALYSIS
Table 8-1: World Cancer Test Market (In Vitro Diagnostic Kits) by Region (North America, EU, Japan, ROW), 2014 and 2019 ($ millions) Table 8-2: World Cancer Test Market (Clinical Laboratory Test Services), 2014 and 2019 ($ millions) Table 8-3: Worldwide Market for Selected Cancer IVD Tests (Sold to ClinicalLabs) (Histology/Cytology, Immunoassays, Flow Cytometry, Rapid Tests, Molecular Assays, CTCs), 2014 and 2019 ($ millions) Figure 8-1: Geographical Distribution of Pap Smear Testing, 2013 Table 8-4: Worldwide Histology/Cytology Sales (Pap Smears, Other [non-Pap] Stains, HPV, Immunohistochemistry, and In Situ Hybridization), 2014 and 2019($ millions) Table 8-5: Cancer Immunoassay Sales, Lab-Based (PSA, CEA, CA 125, AFP,Others), 2014 and 2019 ($ millions) Table 8-6: Rapid Cancer Test Sales by Test Category (FOB, PSA, NMP22, Other)Worldwide, 2014 and 2019 ($ millions)
Note: Product cover images may vary from those shown
3 of 2

Loading
LOADING...

Adroll
adroll